MX2021001292A - Metodos para la modificacion genica de celulas hematopoyeticas. - Google Patents
Metodos para la modificacion genica de celulas hematopoyeticas.Info
- Publication number
- MX2021001292A MX2021001292A MX2021001292A MX2021001292A MX2021001292A MX 2021001292 A MX2021001292 A MX 2021001292A MX 2021001292 A MX2021001292 A MX 2021001292A MX 2021001292 A MX2021001292 A MX 2021001292A MX 2021001292 A MX2021001292 A MX 2021001292A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hematopoietic cells
- gene modification
- relates
- present
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000012239 gene modification Methods 0.000 title abstract 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 title abstract 2
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 2
- 208000016361 genetic disease Diseases 0.000 abstract 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 102000007327 Protamines Human genes 0.000 abstract 1
- 108010007568 Protamines Proteins 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000005017 genetic modification Effects 0.000 abstract 1
- 235000013617 genetically modified food Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960000502 poloxamer Drugs 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 229950008679 protamine sulfate Drugs 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862712146P | 2018-07-30 | 2018-07-30 | |
| PCT/US2019/044237 WO2020028430A1 (en) | 2018-07-30 | 2019-07-30 | Methods for gene modification of hematopoietic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001292A true MX2021001292A (es) | 2021-07-15 |
Family
ID=69232048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001292A MX2021001292A (es) | 2018-07-30 | 2019-07-30 | Metodos para la modificacion genica de celulas hematopoyeticas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210290685A1 (https=) |
| EP (1) | EP3830248A4 (https=) |
| JP (2) | JP7664829B2 (https=) |
| KR (1) | KR20210046004A (https=) |
| CN (1) | CN112888777A (https=) |
| AU (1) | AU2019315438B2 (https=) |
| BR (1) | BR112021001757A2 (https=) |
| CA (1) | CA3106241A1 (https=) |
| IL (2) | IL280465B2 (https=) |
| MX (1) | MX2021001292A (https=) |
| SG (1) | SG11202100025QA (https=) |
| WO (1) | WO2020028430A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055862T2 (hu) | 2016-04-20 | 2021-12-28 | Centro De Investig Energeticas | Készítmények és eljárások PKLR fokozott génexpressziójára |
| SG11202002263TA (en) | 2017-10-16 | 2020-04-29 | Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas | Lentiviral vectors for delivery of pklr to treat pyruvate kinase deficiency |
| WO2019200167A1 (en) | 2018-04-11 | 2019-10-17 | Rocket Pharmaceuticals, Ltd. | Compositions and methods for stem cell transplant |
| MX2020011386A (es) | 2018-04-27 | 2021-01-29 | Spacecraft Seven Llc | Terapia genica para la degeneracion del snc. |
| CN115243705A (zh) * | 2020-05-27 | 2022-10-25 | 苏黎世大学 | 新颖的转导增强剂及其用途 |
| KR20230043869A (ko) | 2020-08-07 | 2023-03-31 | 스페이스크래프트 세븐, 엘엘씨 | Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법 |
| CN114763563B (zh) * | 2021-01-12 | 2024-04-30 | 深圳华大临床检验中心 | 一种提高慢病毒感染效率的方法 |
| AU2022264498A1 (en) | 2021-04-26 | 2023-09-28 | Strm.Bio Incorporated | Compositions and methods related to megakaryocyte-derived extracellular vesicles for fanconi anemia |
| WO2025106604A1 (en) * | 2023-11-14 | 2025-05-22 | The University Of North Carolina At Chapel Hill | Compositions and methods relating to antiviral therapeutics |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL261002B2 (en) * | 2016-02-12 | 2024-07-01 | Bluebird Bio Inc | Vcn enhancer compositions and methods of using the same |
| CA3058735A1 (en) | 2016-06-13 | 2017-12-21 | Bluebird Bio, Inc. | Gene therapy of neuronal ceroid lipofuscinoses |
| KR20240151726A (ko) * | 2016-09-08 | 2024-10-18 | 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. | 판코니 빈혈 환자를 위한 유전자 치료 |
| BR112019011635A2 (pt) | 2016-12-06 | 2019-11-12 | Bluebird Bio Inc | terapia genética para mucopolissacaridose, tipo i |
| JP2020500562A (ja) * | 2016-12-06 | 2020-01-16 | ブルーバード バイオ， インコーポレイテッド | ムコ多糖症ｉｉ型のための遺伝子治療 |
-
2019
- 2019-07-30 KR KR1020217005904A patent/KR20210046004A/ko active Pending
- 2019-07-30 WO PCT/US2019/044237 patent/WO2020028430A1/en not_active Ceased
- 2019-07-30 AU AU2019315438A patent/AU2019315438B2/en active Active
- 2019-07-30 CN CN201980049019.6A patent/CN112888777A/zh active Pending
- 2019-07-30 CA CA3106241A patent/CA3106241A1/en active Pending
- 2019-07-30 MX MX2021001292A patent/MX2021001292A/es unknown
- 2019-07-30 EP EP19844952.2A patent/EP3830248A4/en active Pending
- 2019-07-30 IL IL280465A patent/IL280465B2/en unknown
- 2019-07-30 US US17/264,275 patent/US20210290685A1/en active Pending
- 2019-07-30 JP JP2021505315A patent/JP7664829B2/ja active Active
- 2019-07-30 IL IL316185A patent/IL316185A/en unknown
- 2019-07-30 BR BR112021001757-7A patent/BR112021001757A2/pt unknown
- 2019-07-30 SG SG11202100025QA patent/SG11202100025QA/en unknown
-
2024
- 2024-12-13 JP JP2024218336A patent/JP2025038075A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202100025QA (en) | 2021-01-28 |
| IL280465B2 (en) | 2025-03-01 |
| EP3830248A1 (en) | 2021-06-09 |
| US20210290685A1 (en) | 2021-09-23 |
| JP2021532776A (ja) | 2021-12-02 |
| WO2020028430A1 (en) | 2020-02-06 |
| CN112888777A (zh) | 2021-06-01 |
| JP2025038075A (ja) | 2025-03-18 |
| IL280465B1 (en) | 2024-11-01 |
| AU2019315438B2 (en) | 2026-02-05 |
| AU2019315438A1 (en) | 2021-01-28 |
| JP7664829B2 (ja) | 2025-04-18 |
| IL316185A (en) | 2024-12-01 |
| IL280465A (en) | 2021-03-25 |
| EP3830248A4 (en) | 2022-05-04 |
| KR20210046004A (ko) | 2021-04-27 |
| BR112021001757A2 (pt) | 2021-05-11 |
| CA3106241A1 (en) | 2020-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021001292A (es) | Metodos para la modificacion genica de celulas hematopoyeticas. | |
| MY188987A (en) | Aav vectors for retinal and cns gene therapy | |
| CO2020010270A2 (es) | Vector recombinante para terapia génica de la distrofia muscular de cinturas tipo 2c | |
| WO2018151821A8 (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF | |
| MX2016001204A (es) | Vectores virales adeno-asociados (aav) utiles para transducir tejido adiposo. | |
| ZA201705628B (en) | Methods and compositions for treating genetic eye diseases | |
| PH12017502424A1 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| BR112022008214A2 (pt) | Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina | |
| MX2022013963A (es) | Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas. | |
| EA202290001A1 (ru) | Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута | |
| WO2020093018A8 (en) | A codon optimized otoferlin aav dual vector gene therapy | |
| EP4631509A3 (en) | Recombinant adenoviruses and use thereof | |
| WO2016019144A3 (en) | Gene correction of scid-related genes in hematopoietic stem and progenitor cells | |
| CL2022000292A1 (es) | Partículas virales para uso en el tratamiento de sinucleinopatías tales como enfermedad de parkinson mediante terapia genética | |
| MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
| EA201890351A1 (ru) | Рекомбинантный orf-вирусный вектор | |
| MX2019008105A (es) | Virus. | |
| ZA202304290B (en) | Nucleic acid constructs, viral vectors and viral particles | |
| MX2021004688A (es) | Distrofinas miniaturizadas y usos de las mismas. | |
| EA202092069A1 (ru) | Композиции и способы лечения макулярной дистрофии | |
| PH12021551701A1 (en) | Liver-specific inducible promoters and methods of use thereof | |
| MX2020002148A (es) | Vectores adenoasociados recombinantes. | |
| EP4223320A3 (en) | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) | |
| MX2024009890A (es) | Factores terapeuticos para el tratamiento de enfermedades poliglutaminicas | |
| WO2020188228A8 (en) | Methods of optimising expression and delivery of mitochondrial proteins |